Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Melbourne, Australia, September 26 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamor

Immuron CEO, Steven Lydeamore presentation to

Emerging Growth Conference

Melbourne, Australia, September 26 2024: Immuron

Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented virtually at the Emerging

Growth Conference early on 26 September 2024 (AEST) (25 September 2024, U.S. Eastern Standard Time).

A copy of the presentation being made is included

This release has been authorised by the directors

Chief Executive Officer

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an

Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the

treatment of infectious diseases.

Travelan is an orally administered

passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a digestive tract disorder

that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a highly purified tabletized

preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent

colonization and the pathology associated with travelers' diarrhea. In Australia, Travelan is a listed medicine

on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers' Diarrhea, reduce

the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan is a licensed natural health

product (NPN 80046016) and is indicated to reduce the risk of Travelers' Diarrhea. In the U.S., Travelan is sold as a dietary

supplement for digestive tract protection.

Travelers' diarrhea (TD)

TD is generally defined as the passage of

3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus in

the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited destinations (Leung et

al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income regions

(Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population, are particularly affected

given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012). Diarrhea is the leading infectious

disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic E. coli, Campylobacter spp., and

Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).

Immuron Platform Technology

Immuron's proprietary technology is based

on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly

specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of

the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses

this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying

nature of Immuron's platform technology enables the development of medicines across a large range of infectious diseases. The platform

can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.

IMM-124E (Travelan )

IMM-124E was developed using Immuron's platform

technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during pregnancy with a vaccine containing

the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine to produce high levels of antibodies

against selected surface antigens from the most common strains of ETEC.

The resultant hyperimmune colostrum IMM-124E from

ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I and Flagellin (Sears et

The antibodies produced in IMM-124E have been

found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against a wide range of LPS antigens

including both the variable O-polysaccharide region and the preserved oligosaccharide core R' region of LPS from the 13 serotypes

used in the ETEC vaccine.

IMM-124E is manufactured into a tablet form referred

Immuron is developing IMM-529 as an adjunctive therapy in combination

with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection (CDI). IMM-529 antibodies

targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment of normal gut flora,

providing an attractive oral preventative for recurrent CDI.

Immuron is collaborating with Dr. Dena Lyras and her team at Monash

University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised to generate hyperimmune

bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529 targets Toxin B (TcB),

the spores and the surface layer proteins of the vegetative cells.

This unique 3-target approach has yielded promising results in pre-clinical

infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection of disease recurrence (67%,

P <0.01) and (3) Treatment of primary disease (78.6%, P<0.0001; TcB HBC). Importantly IMM-529 antibodies cross-react with whole

cell lysates of many different human strains of C. diff including hypervirulent strains.

To our knowledge, IMM-529 is, to date, the only investigational drug

that has shown therapeutic potential in all three phases of the disease (Hutton et al., 2017).

Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during

military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012.

Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies

targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5

Leung AK, Robson WL, Davies HD. Travelers' diarrhea. Adv Ther.

Jul-Aug; 23(4): 519-27; 2006

Otto W, Najnigier B, Stelmasiak T and Robins-Browne

RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic

Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862- 868; 2011.

Riddle MS, Sanders JW, Putnam SD, and Tribble

DR. Incidence, etiology, and impact of diarrhea among long-term travelers' (US military and similar populations): A systematic review.

American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.

Sears KT, Tennant SM, Reymann MK, Simon R, Konstantopolos

N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune

Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.

Steffen R. Epidemiology of travelers' diarrhea.

J Travel Med. 24(suppl_1): S2-S5; 2017.

For more information visit: https://www.immuron.com.au/ and https://www.travelan.com

Subscribe for Immuron News: Here

FORWARD-LOOKING STATEMENTS:

This press release may contain "forward-looking statements"

within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended.

Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any

other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are

subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value.

Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy;

our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results

of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating

to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel;

the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual

property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking

to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations

or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

26 September 2024 Steven Lydeamore Chief Executive Officer Investor Presentation NASDAQ: IMRN ASX: IMC

Certain statements made in this presentation are forward - looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," " intends," " plans," " believes," " seeks," "estimates," "guidance" and s imilar expressions are intended to identify forward - looking statements. Although Immuron believes the forward - looking statements are based on reasonable assumptions, they are subject to certain r i sks and uncertainties, some of which are beyond Immuron's control, including those r i sks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ f rom those expressed or forecasted in the forward - looking statements. The forward - looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward - looking statements to reflect events, c i rcumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority. YTD FY 2024 results in this presentation are subject to audit review. SAFE HARBOR STATEMENT

3 Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases 3 as of 24 September 2024 U.S. Department of Defense Research Award for NMRC and WRAIR to develop an enhanced formulation of Travelan IMM - 529 Immuron completes pre - IND meeting with FDA on the development of IMM - 529 Major Shareholders Financial Snapshot 227,998,346 Shares on Issue 15,078,839 Total Options IMC: A$0.105 Last Traded Price IMC: A$0.17/0.065 IMRN: $5.96/1.481 52 week High/Low IMC: A$23.93m Market Cap A$11.7m Cash & Cash Equivalents (as at 30 June 2024) % of CSO Units Holder 34.0 % 77,565,904 BNY Mellon Asset Management 2.4 % 5,500,000 Authentics Australia Pty. Ltd. 1.7 % 3,846,712 Grandlodge 0.9 % 1,954,070 Management & Board Company Overview Two commercially available oral immunotherapeutic products - Travelan and Protectyn 4 clinical programs: Travelan (IMC: Phase 2 CHIM trial), Travelan (USU: Phase 4 field study), CampETEC (NMRC: Phase 2 CHIM trial), IMM - 529 (IMC: Protocol development phase, Phase 2 trial) Business Update Travelan (IMM - 124E) Phase 2 CHIM trial topline results Travelan (IMM - 124E) Travelan Uniformed Services University IMM - 124E Phase 4 trial recruited ~85% of 866 CampETEC Phase 2 clinical trial completed inpatient phase Results & Outlook Sales 1 Jul 23 to 30 June 24 of A$4.9 million up 172% on pcp (unaudited) Evaluating options to enter international markets Evaluating options to add to marketed products portfolio

4 Travelan record sales Global + Full Year FY2024 AUD$4.9 million up 172% on (prior comparative period) pcp + June 2024 Quarter AUD$1.3 million up 277% on pcp and 5% on last quarter Australia + Full Year 2024 AUD$3.7 million up 236% on pcp + June 2024 Quarter AUD$1.0 million up 247% on pcp and 13% on last quarter USA + Record annual sales + Full Year 2024 AUD$1.1 million up 67% on pcp + June 2024 Quarter AUD$0.3 million up 462% on pcp; down 14% on last quarter 0 1,000 2,000 3,000 4,000 5,000 6,000 FY19 FY20 FY21 FY22 FY23 FY24 Net Sales A$'000